Pete Stark, D-Calif., is floating a proposal to turn into a statutory requirement the CMS guidance that Part D plans must cover "all or substantially all" drugs in six classes
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.
Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.
The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.
